Shionogi & Co., Ltd. (SGIOF)

Market Cap	15.35B
Revenue (ttm)	3.05B
Net Income (ttm)	1.24B
Shares Out	n/a
EPS (ttm)	1.46
PE Ratio	12.36
Forward PE	n/a
Dividend	0.44 (2.34%)
Ex-Dividend Date	Sep 29, 2025

Volume	101
Average Volume	1,278
Open	19.00
Previous Close	17.96
Day's Range	19.00 - 19.00
52-Week Range	12.21 - 19.00
Beta	0.14
RSI	60.68
Earnings Date	Oct 27, 2025

About Shionogi &

Shionogi & Co., Ltd. researches, develops, manufactures, and distributes pharmaceuticals, diagnostic reagents, and medical devices. It offers and develops drugs in the areas of infectious diseases, COVID-19, tumors, sclerosis, pomp, fragile X syndrome, and other diseases. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1878
• Employees: 4,955
• Stock Exchange: OTCMKTS
• Ticker Symbol: SGIOF

Financial Performance

In 2024, Shionogi &'s revenue was 438.27 billion, an increase of 0.73% compared to the previous year's 435.08 billion. Earnings were 170.44 billion, an increase of 5.19%.

Financial numbers in JPY